Market Intelligence, Clinical Progress, and High-Purity Reagents for Channel-Targeted Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AQP3 drug discovery across modalities.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | AQP3 Extracellular Loop Peptides (>95% purity) and HEK293-expressed Full-Length Recombinant Protein (detergent-solubilized, native glycosylation) | View AQP3 Products |
| Gene Delivery | AQP3 Promise-ORF Lentivirus Premade Particles for stable cell line generation; preserves native multi-pass membrane topology | View AQP3 Products |
| Benchmark Ab | Anti-AQP3 Recombinant Control Antibody (sequence-verified, endotoxin-controlled) for Western blot, IHC, and FACS | View AQP3 Products |
| Validator | AQP3 siRNA Set for knockdown verification in functional permeability and specificity assays | View AQP3 Products |
| Related Target A | AQP1 — Water-selective channel; essential for cross-reactivity and selectivity screening | View AQP1 Products |
| Related Target B | AQP4 — CNS aquaporin; pharmacological reference for channel-targeting modalities | View AQP4 Products |
| Related Target C | EGFR — Synergistic pathway partner; co-localizes with AQP3 to drive tumor metastasis | View EGFR Products |
| Related Target D | CD44 — Hyaluronic acid receptor; interacting partner in cell migration and EMT | View CD44 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex membrane protein conformation (multi-pass topology) | Lentivirus-based stable HEK293/CHO cell lines preserve native folding and glycosylation |
| Aquaporin family selectivity screening (AQP1, AQP4, AQP5, AQP7) | Sequence-verified lentivirus expression systems for parallel counter-screening |
| Lack of validated screening controls and off-target mitigation | Benchmark antibodies and siRNA included for target engagement validation |
| Detection of extracellular loop binding in native state | Cell-surface FACS using full-length lentivirus-transduced cells with native loop presentation |
Live AQP3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
AQP3 (Aquaporin-3) is a dual water/glycerol channel (aquaglyceroporin) that plays a central role in epidermal hydration, cell proliferation, and tumor metastasis (breast, gastric, melanoma, NSCLC). Currently, AQP3 drug discovery is almost entirely at the preclinical stage, with no disclosed Phase I candidates—representing a clear first-in-class opportunity. The field is transitioning from traditional generic inhibitors toward highly selective small molecules and engineered biologics (monoclonal antibodies and ADCs) targeting the extracellular loops. Key R&D drivers include tumor microenvironment metabolic reprogramming via glycerol transport blockade, dermatological applications (psoriasis, atopic dermatitis), and combination therapies with EGFR TKIs to overcome resistance in NSCLC. The next wave of innovation will require native-conformation assay systems, family-selective screening panels, and robust internalization assays for ADC development.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Academic spin-offs, preclinical biotechs | Solid tumors (breast, gastric), melanoma | Cell-based osmotic/glycerol transport assay (need AQP3-stable cell line) |
| siRNA / shRNA | Early-stage discovery biotechs | Refractory solid tumors | Knockdown validation (need AQP3 siRNA + qPCR/flow cytometry) |
| Monoclonal Antibodies | Early-stage innovators | Metastatic cancers, wound healing | Binding validation via native conformation cell line (FACS) |
| Topical Inhibitors | Dermatology pharma | Psoriasis, atopic dermatitis | Functional permeability assays (need specific siRNA for specificity) |
| ADC (Future Pipeline) | Oncology leaders | Overexpressing refractory tumors | Internalization assay (need precise flow-cytometry-validated cell lines) |
Key Mutation Reference
- rs34942735 (dbSNP): A documented variant in AQP3 (UniProt Q92482 VAR_025089). This mutation may influence protein stability or channel function; relevant for assay design and patient stratification in precision oncology studies.
Note: All product links reference TarMart’s centralized catalog for AQP3 and related targets.